Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRT7732 |
| Synonyms | |
| Therapy Description |
PRT7732 is a Smarca2 degrader, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 4503). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRT7732 | PRT-7732|PRT 7732 | PRT7732 is a Smarca2 degrader, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 4503). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SMARCA4 loss | Advanced Solid Tumor | predicted - sensitive | PRT7732 | Preclinical - Cell culture | Actionable | In a preclinical study, PRT7732 inhibited proliferation of SMARCA4-deficient cancer cell lines in culture (Cancer Res (2024) 84 (6_Supplement): 4503). | detail... |
| SMARCA4 loss | lung cancer | predicted - sensitive | PRT7732 | Preclinical | Actionable | In a preclinical study, PRT7732 inhibited tumor growth in a SMARCA4-deficient lung cancer xenograft model (Cancer Res (2024) 84 (6_Supplement): 4503). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06560645 | Phase I | PRT7732 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Active, not recruiting | USA | ESP | DEU | AUS | 2 |